Strategies to improve cancer care in the field of urothelial carcinoma (UC) in the elderly or in
patients unfit to receive cisplatin treatment are urgently needed. This effort requires …

Background The majority of patients with advanced urothelial cancer are elderly, but data
regarding this specific age group are limited. We compared the tolerability and efficacy of …

Study Type–Therapy (case series) Level of Evidence 4 OBJECTIVE To study guideline
recommendation (GR)‐concordance rates of treatment in elderly patients with urothelial …

The evolving treatment landscape of advanced urothelial carc... : Current Opinion in Oncology
The evolving treatment landscape of advanced urothelial carcinoma : Current Opinion in …

In recent years the introduction of immunotherapy has importantly changed the treatment
landscape of advanced urothelial carcinoma. Several immune checkpoint inhibitors are now …

Introduction We conducted this study to determine if, in appropriately selected elderly
patients receiving neoadjuvant chemotherapy (NAC), clinical outcomes including pathologic …

Patients with urothelial carcinoma tend to be older and frailer with a large number of chronic
medical conditions. This is particularly pronounced in those with unresectable locally …

Background Patients with advanced urothelial carcinoma (UC) have poor outcomes, with 5-
year survival rates of< 5% for those with metastatic, stage IV disease. We have reviewed …

Opinion statement Bladder cancer is a complex disease of older patients with coexisting
medical problems requiring multimodal therapy. For patients with localized bladder cancer …

Introduction This large-scale, US-based study characterized real-world treatment patterns
and clinical outcomes in patients with advanced or metastatic urothelial carcinoma (aUC) …